Background: Folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and oxaliplatin and capecitabine (XELOX) are the most widely used chemotherapy regimens for treating metastatic colorectal carcinoma (CRC). These regimens are associated with various adverse reactions, including neuropathy and hand-foot syndrome (HFS). Silymarin, a flavonoid derived from , has a wide range of biological activities. It has been used to counteract chemotherapy side effects due to its antioxidant, anti-apoptotic, and anti-inflammatory properties.

Objectives: The purpose of this study was to assess the preventive effect of nano-silymarin on neuropathy and HFS induced by the FOLFOX6 and XELOX regimens.

Methods: A randomized, triple-blinded, placebo-controlled clinical trial was conducted on 60 patients who were randomly assigned to receive 70 mg capsules containing 15% silymarin nano micelles twice a day after meals, starting from the first day of the first chemotherapy course and continuing for six courses of the XELOX or m-FOLFOX6 regimen. The severity of adverse effects was assessed after the third and sixth courses based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.

Results: The median CTCAE scores for HFS and neuropathy were significantly lower in the nano-silymarin group at the end of the third course (P < 0.001). However, the difference remained significant only for HFS at the end of the sixth course (P = 0.022). Additionally, the scores increased significantly in both the placebo and nano-silymarin groups during the therapy (P < 0.05).

Conclusions: Nano-silymarin may be considered an adjuvant medication for the prevention of certain chemotherapy-induced adverse reactions. Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892790PMC
http://dx.doi.org/10.5812/ijpr-152364DOI Listing

Publication Analysis

Top Keywords

hand-foot syndrome
8
xelox m-folfox6
8
metastatic colorectal
8
clinical trial
8
adverse reactions
8
nano-silymarin
6
evaluation oral
4
oral nano-silymarin
4
nano-silymarin formulation
4
formulation efficacy
4

Similar Publications

Background: Folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and oxaliplatin and capecitabine (XELOX) are the most widely used chemotherapy regimens for treating metastatic colorectal carcinoma (CRC). These regimens are associated with various adverse reactions, including neuropathy and hand-foot syndrome (HFS). Silymarin, a flavonoid derived from , has a wide range of biological activities.

View Article and Find Full Text PDF

A questionnaire-based cross-sectional survey of cutaneous adverse events in cancer patients treated with molecular targeted therapy and immunotherapies.

Support Care Cancer

March 2025

Department of Allergy & Immunology, Department of Dermatology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China.

Background: Advances in anticancer treatments have significantly improved disease control and progression-free survival. These therapies are associated with various adverse events (AEs), especially cutaneous toxicities. However, there is a paucity of patient-reported outcomes on cutaneous AEs (CAEs) and associated alternation of quality of life (QoL) in cancer patients.

View Article and Find Full Text PDF

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis.

BMC Womens Health

March 2025

Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines & School of Medical Instruments, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China.

Background: This study aimed to evaluate the efficacy and safety of docetaxel plus capecitabine (TX) and docetaxel plus epirubicin (TE) in the treatment of human epidermal growth factor 2 (HER2)-negative breast cancer.

Methods: Relevant studies assessing the efficacy and safety of TX versus TE were systematically searched from PubMed, Cochrane Library, Embase, and Web of Science databases until February 6, 2025. Progression-free survival (PFS), and clinical response, including the overall response rate (ORR), disease control rate (DCR), and grade 3/4 adverse events were compared.

View Article and Find Full Text PDF

The cerebellum, a lateralised organ, plays a crucial role in motor control. Still, its involvement in hand and foot dominance remains inadequately understood, primarily in the right and left-side dominant population. A potential manifestation of this lateralisation is the neocerebellar extinction syndrome, previously linked to mild muscle hypotonia and moderate passivity in the non-preferred hand.

View Article and Find Full Text PDF

Background: Isolated 20q deletion [del(20q)] is a recurrent favorable abnormality in myelodysplastic syndrome (MDS) and may cause deletion of the ASXL1 gene. Meanwhile, ASXL1 mutations are also common in individuals with MDS. This study aimed to describe the biological and clinical implications of ASXL1 mutations and deletion in newly diagnosed MDS patients with isolated del(20q).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!